704 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
ABBV AbbVie Inc. $95.37 $144.42B N/A
Article Searches
Why AbbVie (ABBV) is a Great Dividend Stock Right Now http://www.zacks.com/stock/news/404855/why-abbvie-abbv-is-a-great-dividend-stock-right-now?cid=CS-ZC-FT-404855 Apr 29, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
ABBV: BMO Capital Markets ups to Market Perform http://www.briefing.com/investor/popuppages/articlepopup.aspx?articleId=UD20190429074930 Apr 29, 2019 - BMO Capital Markets issues rating change for ABBV
AbbVie Inc. (ABBV) CEO Rick Gonzalez on Q1 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4256898-abbvie-inc-abbv-ceo-rick-gonzalez-q1-2019-results-earnings-call-transcript?source=feed_sector_healthcare Apr 25, 2019 - AbbVie Inc. (NYSE:ABBV) Q1 2019 Earnings Conference Call April 25, 2019, 09:00 AM ET Company Participants Elizabeth Shea - VP, IR Rick Gonzalez - Chairman and CEO Michael Severino - Vice Chairman and
AbbVie Inc (ABBV) Q1 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2019/04/25/abbvie-inc-abbv-q1-2019-earnings-call-transcript.aspx?source=iedfolrf0000001 Apr 25, 2019 - ABBV earnings call for the period ending March 31, 2019.
Pfizer (PFE) to Report Q1 Earnings: Will It Beat Estimates? http://www.zacks.com/stock/news/398971/pfizer-pfe-to-report-q1-earnings-will-it-beat-estimates?cid=CS-ZC-FT-398971 Apr 24, 2019 - While Pfizer's (PFE) key drugs like Ibrance and Xeljanz are likely to drive Q1 sales, genericization of key drugs and weak sales in the EH segment will hurt.
5 Turnaround Earnings Charts You Must See http://www.zacks.com/stock/news/398944/5-turnaround-earnings-charts-you-must-see?cid=CS-ZC-FT-398944 Apr 24, 2019 - They were once some of the hottest stocks on the Street. Are they returning to greatness?
Why Earnings Season Could Be Great for AbbVie (ABBV) http://www.zacks.com/stock/news/398839/why-earnings-season-could-be-great-for-abbvie-abbv?cid=CS-ZC-FT-398839 Apr 24, 2019 - AbbVie (ABBV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is a Beat in Store for AbbVie (ABBV) This Earnings Season? http://www.zacks.com/stock/news/390036/is-a-beat-in-store-for-abbvie-abbv-this-earnings-season?cid=CS-ZC-FT-390036 Apr 22, 2019 - Strong growth of Imbruvica and Mavyret are expected to drive AbbVie (ABBV) first-quarter sales. Declining ex-U.S. Humira sales are likely to be an overhang on the top line.
Here Are the Key Takeaways From J&J's Q1 Earnings Report http://www.zacks.com/stock/news/386860/here-are-the-key-takeaways-from-jjs-q1-earnings-report?cid=CS-ZC-FT-386860 Apr 18, 2019 - Let's have a look at some of the highlights of J&J's (JNJ) first-quarter 2019 results.
J&J (JNJ) Beats on Q1 Earnings, Ups 2019 Sales Growth View http://www.zacks.com/stock/news/382057/jj-jnj-beats-on-q1-earnings-ups-2019-sales-growth-view?cid=CS-ZC-FT-382057 Apr 16, 2019 - J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2019 and raises 2019 guidance for operational sales and adjusted operational EPS growth. Shares up in pre-market trading.

Pages: 123456789...71

<<<Page 4>